Abstract
Replicon particles of Rift Valley fever virus, referred to as nonspreading Rift Valley fever virus (NSR), are intrinsically safe and highly immunogenic. Here, we demonstrate that NSR-infected human dendritic cells can activate CD8(+) T cells in vitro and that prophylactic and therapeutic vaccinations of mice with NSR encoding a tumor-associated CD8 peptide can control the outgrowth of lymphoma cells in vivo. These results suggest that the NSR system holds promise for cancer immunotherapy.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
MeSH terms
-
Animals
-
CD8-Positive T-Lymphocytes / immunology*
-
Cancer Vaccines / immunology
-
Dendritic Cells / immunology*
-
Dendritic Cells / virology
-
Epitopes / genetics
-
Epitopes / immunology
-
Humans
-
Immunotherapy / methods*
-
Lymphocyte Activation / immunology
-
Lymphoma / immunology*
-
Lymphoma / prevention & control
-
Lymphoma / therapy
-
Mice
-
Mice, Inbred C57BL
-
Phosphoproteins / genetics
-
Phosphoproteins / immunology
-
Rift Valley fever virus / genetics
-
Rift Valley fever virus / immunology*
-
Vaccination
-
Viral Matrix Proteins / genetics
-
Viral Matrix Proteins / immunology
Substances
-
Cancer Vaccines
-
Epitopes
-
Phosphoproteins
-
Viral Matrix Proteins
-
cytomegalovirus matrix protein 65kDa